Opportunity ID: 342447

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-22-TBIPHRP-TRA
Funding Opportunity Title: DoD Traumatic Brain Injury and Psychological Health, Translational Research Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 10
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jul 15, 2022
Last Updated Date: Jul 15, 2022
Original Closing Date for Applications: Sep 14, 2022
Current Closing Date for Applications: Sep 14, 2022
Archive Date: Oct 14, 2022
Estimated Total Program Funding: $15,500,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

The FY22 TBIPHRP TRA is intended to support translational research that will accelerate the movement of promising ideas in psychological health conditions and/or TBI research into clinical  applications, including healthcare products, technologies, and/or clinical practice guidelines.

Applicants should not view translational research as a one-way continuum from bench to bedside.  The research plan is encouraged to involve a reciprocal flow of ideas and information between basic and clinical science. As such, applications must include preliminary and/or published data to support the proposed research project.

Applications to the FY22 TBIPHRP TRA may include preclinical and/or clinical research involving human subjects and human anatomical substances. The FY22 TBIPHRP TRA may also support ancillary studies that are associated with an ongoing or completed clinical trial and projects that optimize the design of future clinical trials.

If animal models are proposed, consider the following:

•   Pairing clinical populations to animal models in order to validate the clinical relevance and development of prevention, assessment, and treatment solutions is encouraged.

•   Proposed animal models should be well justified, supported within the literature, and clearly align with clinical relevance to the human condition.

The FY22 TBIPHRP TRA also allows funding for a pilot/exploratory clinical trial as PART of the funded research project where limited clinical testing of a novel knowledge product,3 intervention, or device is necessary to inform the next step in the continuum of translational research. Such pilot/exploratory clinical trial studies should be small, make up only a portion of the research proposed in the Statement of Work (SOW), and be utilized to establish the feasibility of a 

potential approach or to aid in device or intervention refinement. Applications that include large-scale clinical trials do not meet the intent of the mechanism. Applications that consist entirely of a pilot/exploratory clinical trial or multiple pilot/exploratory clinical trials may be administratively withdrawn.

Alternative trial designs to traditional randomized clinical trials are allowed, but should be appropriate to the objective of the trial. Applications that include a pilot/exploratory clinical trial as part of the proposed research will have additional submission requirements and review criteria. Funded trials are required to post a copy of the Institutional Review Board (IRB)- approved informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in the Code of Federal Regulations, Title 32, Part 219 (32 CFR 219). This award may not be used to support studies requiring an exception from informed consent (EFIC).

Applications that consist entirely of multiple pilot/exploratory clinical trials or solely of a pilot/exploratory clinical trial are not permitted under this funding mechanism and should consider submitting to the following FY22 TBIPHRP funding opportunities:

•   Clinical Trial Award (Funding Opportunity Number: W81XWH-22-S-TBIPH1)

•   Focused Program Award (Funding Opportunity Number: W81XWH-22-S-TBIPH2)

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

Version History

Version Modification Description Updated Date

Folder 342447 Full Announcement-FY22 TBIPHRP TRA -> W81XWH-22-TBIPHRP-TRA-GG2.pdf

Packages

Agency Contact Information: CDMRP Help Desk
Phone: 301-682-5507
Email: help@eBRAP.org
Email: help@eBRAP.org
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00276033 Jul 15, 2022 Sep 14, 2022 View

Package 1

Mandatory forms

342447 RR_SF424_5_0-5.0.pdf

342447 AttachmentForm_1_2-1.2.pdf

342447 RR_PersonalData_1_2-1.2.pdf

342447 RR_KeyPersonExpanded_4_0-4.0.pdf

342447 RR_Budget_3_0-3.0.pdf

342447 PerformanceSite_4_0-4.0.pdf

Optional forms

342447 RR_SubawardBudget30_3_0-3.0.pdf

2025-07-13T12:04:45-05:00

Share This Post, Choose Your Platform!

About the Author: